Artelo Biosciences announces publication of paper on FABP inhibitor program

Artelo Biosciences (ARTL) welcomed the publication of a comprehensive review in Neurobiology of Disease, titled “Fatty acid binding proteins and their involvement in anxiety and mood disorders,” that underscores the therapeutic potential of Fatty Acid Binding Protein inhibitors in treating mood and anxiety disorders. The peer-reviewed article was co-authored by Doctor Steven Laviolette, Professor in the Schulich School of Medicine along with other researchers from the University of Western Ontario, Canada, details extensive preclinical evidence supporting FABP5, FABP3, and FABP7 as key regulators of lipid trafficking, neuroinflammatory signaling, and endocannabinoid tone – mechanisms critically involved in the pathophysiology of anxiety and depression. “We believe this paper provides compelling evidence that inhibition of FABP5 can significantly elevate anandamide levels, modulate stress-related neurocircuits, and produce robust anxiety-reducing and antidepressant effects without the cognitive side effects typically seen with current standard of care,” said Gregory D. Gorgas, CEO. “These findings add to the growing body of research supporting FABPs as promising targets for the treatment of wide array of neuropsychiatric conditions.”